Privately-held Swiss drugmaker Ewopharma revealed yesterday that, as of April 1 this year, it has acquired the rights to commercialize several of Japanese pharma major Eisai's (TYO: 4523) products in 11 countries in Central and Eastern Europe (CEE).
Ewopharma will commercialize cancer drug Halaven (eribulin mesylate) in nine countries within the European Union (Bulgaria, Croatia, Estonia, Hungary, Latvia, Lithuania, Poland, Romania and Slovenia) and in two countries outside of the EU (Bosnia & Herzegovina and Serbia). Ewopharma will also commercialize Targretin (bexarotene), also for cancer, in Hungary and Poland as well as epilepsy drug Zonegran (zonisamide) in Hungary.
Ewopharma will be responsible for all aspects of pricing, reimbursement, marketing and distribution, while Eisai will supply product and also provide significant product training and support across the relevant brands.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze